RVV — Revive Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- CA$6.54m
- CA$6.58m
Annual cashflow statement for Revive Therapeutics, fiscal year end - June 30th, CAD millions except per share, conversion factor applied.
2021 June 30th | 2022 June 30th | 2023 June 30th | 2024 June 30th | 2025 June 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -20.1 | -17.8 | -6.32 | -5.62 | -11 |
| Depreciation | |||||
| Non-Cash Items | 11.1 | 1.2 | 1.04 | 2.51 | 9.64 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.706 | 3.54 | -0.748 | -0.186 | 0.603 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -8.31 | -13.1 | -6.03 | -3.29 | -0.768 |
| Capital Expenditures | -3 | 0 | — | — | — |
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | 0.281 | 0 | — | — | -0.03 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -2.72 | 0 | — | — | -0.03 |
| Financing Cash Flow Items | -2.45 | 0 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 26.2 | 0.376 | 4.2 | 1.98 | 0.039 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 15.2 | -12.7 | -1.83 | -1.31 | -0.759 |